Mary E. O'Hearn, M.D.
Mary E. O'Hearn, M.D.
Medical Director, OHSU HIV Clinic
Division of General Internal Medicine and Geriatrics
Education and Training
B.A. - University of California, 1980
M.D. - Stanford University, 1986
An experienced educator and internist, Dr. O`Hearn concentrates on medical care for HIV-infected adults. She has cared for persons living with HIV for the past 20 years. She is the clinical director of the HIV Clinic , a multidisciplinary clinic which offers primary care services to HIV-infected adults, as well as mental health, pharmacy and case-management services. She spends her free time with her husband, daughter, and Jack Russell terrier. She has traveled extensively and enjoys reading, eating, and hiking.
"I have been involved in caring for persons living with HIV for the past 20 years. I have seen truly miraculous changes in the treatment of my patients over this time period. I feel very privileged to have been able to witness these changes and grow together with my patients."
Diplomate, American Board of Internal Medicine, 1989
HIV Specialist, AMerican Academy of HIV Medicine, 2002
Involvement in several pharmaceutical sponsored trials evaluating the efficacy of investigational antiretroviral agents. I continue to be involved with overseeing data entry into a national data base (NA-ACCORD) tracking non-HIV related complications in our patient population. I have completed entry of non-HIV cancers , End Stage Renal Disease and End Stage Liver Disease and will begin entering data regarding cardiovascular events. These data have proved invaluable in understanding the changing risks for morbidity and mortality in the HIV population in the U.S. Current Projects.
- Murphy M, O'Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiviral regimen containing didanosine. Clinical Infectious Diseases 2003; 36(8):1082-5.
- Lalezari J, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor for drug resistant HIV infections in North and South America. New England Journal of Medicine 2003; 348(22):2175-85.
- Nelson M, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1infected patients in the T-20 versus optimized background regimen: TORO 1 and 2. Journal AIDS 2005; 40(4):404-12.
- Trottier B, et al. Safety of Enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1 infected adults over 48 weeks. JAIDS 2005; 40(4):413-21.
I follow over 200 HIV infected patients as their primary care provider as well as provide HIV consultative services for patients who live outside the Portland metropolitan area. We utilize a chronic care model for the management of our patients with close coordination of care with nurse care managers, social workers, pharmacist and mental health providers. I also continue to consult on HIV patients in the Oregon State Correctional Institute by performing regular on site visits with incarcerated HIV infected individuals. Our collaboration with Corrections has been helpful in improving outcomes and containing health care costs.
Patient Care Locations
OHSU HIV/AIDS Clinic, Physicians Pavilion
I continue to work with Internal Medicine residents rotating thru the OHSU HIV Clinic as part of the Ambulatory Care Curriculum. The medicine residents (PGY 1) attend 6 clinics over a 3 month period. The rotation includes a series of didactic talks covering topics in outpatient HIV care, as well as seeing patients in the HIV faculty practice. This has allowed our residents to develop a greater understanding of the management of the HIV infected patient in the outpatient setting. We have been successful in increasing awareness of the non-HIV related complications seen in persons living with HIV.